CARMIEL, Israel, Sept. 12, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) announced the pricing of $60 million principal amount of its 4.50% Convertible Notes due 2018 (the "Notes") through a private offering. The Company has granted the initial purchaser an option to purchase up to an additional $9 million principal amount of the Notes on the same terms and conditions, to cover over-allotments, if any, exercisable for 30 days after the pricing date of the Notes. The offering is expected to close on September 18, 2013, subject to satisfaction of customary closing conditions.
Protalix BioTherapeutics Announces Pricing Of $60 Million Offering Of Convertible Notes
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts